ClinicalTrials.Veeva

Menu
O

Olympian Clinical Research | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lebrikizumab
Rapastinel
Ixekizumab
Guselkumab
Dupilumab
CP-690,550
PF-06700841
Ruxolitinib
SUVN-502
BIIB092

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 50 total trials

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accept...

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: SEP-363856

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or...

Active, not recruiting
Hidradenitis Suppurativa
Drug: secukinumab

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Active, not recruiting
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 2

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Trial sponsors

Lilly logo
Pfizer logo
Incyte logo
Allergan logo
Janssen (J&J Innovative Medicine) logo
Biohaven logo
LEO Pharma logo
Otsuka logo
A
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems